Aim To assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer's disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia. Methods A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method. Results The level of empirical study evidence for the use of FDG-PET was considered good for the discrimination of DLB and AD; fair for discriminating FTLD from AD; poor for atypical AD; and lacking for discriminating DLB from FTLD, AD from VaD, and for pseudodementia. Delphi voting led to consensus in all scenarios within two iterations. Panellists supported the use of FDG-PET for all PICOs-including those where study evidence was poor or lacking-based on its negative predictive value and on the assistance it provides when typical patterns of hypometabolism for a given diagnosis are observed. Conclusion Although there is an overall lack of evidence on which to base strong recommendations, it was generally concluded that FDG-PET has a diagnostic role in all scenarios. Prospective studies targeting diagnostically uncertain patients for assessing the added value of FDG-PET would be highly desirable.
Background FDG-PET has long been used to assist the clinical diagnostic work-up for the main forms of dementia and, although inconsistently, is usually reimbursed in Europe for this indication (Table 1) . Clinical guidelines for its diagnostic use in dementia are, however, still lacking, which led the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) to launch a joint initiative to guide clinicians in the use of the examination. The initiative included a set of 21 clinical questions that were addressed on the basis of literature evidence and expert consensus [1] .
In this paper, we report the evidence assessment performed with regard to the added value of FDG-PET in diagnosing and differentiating the main forms of dementing neurodegenerative disorders-namely Alzheimer's disease (AD), both in its typical memory-onset presentation and in atypical presentations; frontotemporal lobar degeneration (FTLD); dementia with Lewy bodies (DLB); vascular dementia (VaD); and pseudodementia. Consensus recommendations were then formulated.
Six literature searches were performed to assess the quality of evidence supporting the utility of FDG-PET in the differential diagnosis among the above forms of dementing disorders.
Methods
Seven panellists, four from EANM and three from EAN, were appointed to formulate recommendations taking into consideration the value of FDG-PET as an addition to clinical-neuropsychological examination for the diagnosis and management of patients with different types of dementing neurodegenerative disorders. Consensus recommendations were developed through a Delphi procedure, where panellists were asked to vote based on their expertise and on the literature evidence, assessed as follows.
Each evidence search and synthesis followed the PICO (population, intervention, comparison, outcome) approach, and was performed based on PICO question keyword strings, which are reported in [2] . One designated panellist per PICO performed the search and extracted an initial long list of studies. The studies for inclusion in the analysis were then finalised by applying the PICO-specific eligibility criteria (see 'Eligibility criteria' section). A methodology group (comprising three with experience in research methods and two clinical researchers) extracted the data from these selected studies, assessed their methodological quality and performed an assessment on the quality of evidence based on the European Federation of Neurological Societies (EFNS) guidance [3] and in the context of the overall literature on FDG-PET [2] . 
Eligibility criteria
Only original full papers published in English in international journals were considered, excluding reviews, management guidelines, abstracts and grey literature. Any sample size was accepted if pathology was the reference standard for diagnosis. Without pathological confirmation, the minimum sample size was five for atypical forms of AD and 20 for the AD vs FTLD contrast. No sample size limit was set for any of the other PICOs.
Literature search
The electronic search strategy, developed and tested with panellists, was performed through predefined keyword strings relating to the specific PICO question. These strings included a selection of terms taken from a largely inclusive literature selection in order to capture all variants for the same keyword. The strings were made up of a common part ('FDG-PET') and a part specific to each PICO [2] . Literature searches were performed using Medline, Embase, PubMed and Google Scholar databases, with cross-referencing, as of November 2015. We adhered to standards of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) in reporting the findings of this review [4] . An initial independent screening of all included studies was performed by an expert neurologist, who could include additional papers based on personal knowledge or tracking from references of papers. The full texts of these potentially eligible studies were then independently assessed for eligibility by a methodology team member.
Data extraction and quality assessment
We extracted data considering 80 variables that allowed evaluation of study features, population of interest, index test and gold/reference standard. Critical outcomes were validated measures of test performance (accuracy, sensitivity, specificity, area under the curve [AUC], positive and negative predictive value [PPV and NPV, respectively], and positive and negative likelihood ratios [LR+ and LR−, respectively]). Another outcome, specific to PICO 7, was the added diagnostic value of FDG-PET expressed as change in diagnosis and treatment. Data extractors were as follows: DA for PICOs 7, 9, 10; JR for PICO 8; CF for PICO 11; no papers were available for PICO 14 (see [2] in this issue for more detail).
The quality of evidence was consensually assessed within the methodology team based on study design, gold/reference standard, FDG-PET image assessment (visual or semiquantitative methods), risk of bias, index test imprecision, applicability, effect size and effect inconsistency. A final assessment of relative availability of evidence was formulated, taking into account evidence availability among all 21 PICOs. This ranking was summarised as either lacking, poor, fair or good. For further details about data extraction and quality assessment, see [2] in this issue.
In our terminology, we distinguished syndromes from pathophysiologies, consistent with current National Institute on Aging-Alzheimer's Association (NIA-AA) and International Working Group (IWG) criteria [5, 6] . Regarding FTLD, unless differently referenced (e.g. [7] ), we adopted the inclusive 1998 definition [8] , treating separately only the linguistic variants where specified.
Results
For the six PICOs included in this review, only 22 of the 87 papers examined contained the critical outcomes for the comparison of interest (Fig. 1) . The diagnoses covered by these PICOs are known to have distinct patterns of hypometabolism. Specifically, the profiles are as follows: bilateral predominant medial and lateral temporo-parietal, with less pronounced prefrontal, hypometabolism in typical AD (AD-memory); the same lobar distribution of hypometabolism as typical AD but with marked left hemispheric lateralisation for the aphasic form of AD (AD-language); predominant posterior temporoparietal and occipital hypometabolism for the posterior cortical atrophy (PCA) variant of AD (AD-visuospatial); predominant occipito-parietal hypometabolism with less prominent frontal hypometabolism and relative preservation of the posterior cingulate region for DLB; prefrontal and/or anterior temporal hypometabolism in FTLD; hypometabolism co-localised to ischaemic lesions (on structural imaging)/hypometabolic regions not conforming to the recognised patterns seen for degenerative dementias in VaD; and preserved cerebral metabolism (relative to the apparent degree of cognitive impairment) in pseudodementia (Fig. 2) .
Our data extraction and assessment found evidence lacking (meaning a lack of actual studies as opposed to evidence of a lack of utility) for the clinical use of FDG-PET in discriminating VaD from AD, DLB from FTLD, and neurodegenerative dementias from pseudodementia. The level of available evidence was rated as poor for differentiating among atypical forms of AD, fair for distinguishing between AD and FTLD, and good for differentiating AD from DLB. Nonetheless, consistent with recommendations in disease-specific clinical criteria [1, 6, 7, [9] [10] [11] [12] [13] [14] [15] , the panellists supported clinical use according to known disease-related metabolic patterns ( Table 2 ).
PICO 7: Atypical AD
Among the 73 papers identified and screened by the designated panellist (AD), 15 were sent to the methodology team for data extraction and assessment (see Fig. 1 -PICO 7) . Five papers were excluded, since comparison was made between patients with atypical dementia and healthy people [21] [22] [23] [24] [25] . The data extraction table is available at: https://drive.google. com/open?id=0B0_JB3wzTvbpZEd4Z083OThxNDg.
Critical outcomes were available in four of the examined papers (Table 3 ). These studies included inhomogeneous patient samples; thus the main results are reported separately for each paper. In patients with 'atypical/unclear dementia', an FDG-PET scan led to a diagnostic change in 59.5% of the cases, and to increased prescription of cholinesterase inhibitors (ChEIs) from 13.8% to 38.3% [26] . In a population affected by the main AD variants (AD-memory, AD-visuospatial and ADlanguage), distinct hypometabolism patterns were found in the AD-language dominant (left inferior frontal and left temporoparietal; AUC = 0.82, p = 0.011) and AD-visuospatial dominant (bilateral occipito-parieto-temporal, AUC = 0.85, p = 0.009; and right posterior cingulate cortex/precuneus and right lateral parietal, AUC = 0.69, p = 0.045) presentations. A trend was also found for AD-memory dominant cases (AUC = 0.65; p = 0.062) for hypometabolism in bilateral inferior frontal, cuneus and inferior temporal regions, and right inferior parietal lobe [27] . The logopenic variant of PPA (lvPPA)-the PPA variant most often associated with AD pathology-could be distinguished from AD-memory (AUC = 0.89) based on hypometabolism in the right medial temporal and posterior cingulate gyri, the left inferior, middle and superior temporal lobes, and left supramarginal gyrus [28] (see also [16] in this issue for discussion of AD-language in the context of other primary progressive aphasias). Patients affected by PCA were distinguished from DLB on the basis of FDG-PET pattern with 83% sensitivity, 85% specificity and 83% accuracy, and from the pooled AD and DLB with 83% sensitivity, 93% specificity, 90.9% accuracy and 91% AUC [29] . Figure 2 shows some examples of typical hypometabolic patterns in sample patients.
Relative to the 21 PICOs of the entire project [1, 2] , the availability of formal evidence supporting the utility of clinical use of FDG-PET in differentiating AD dementia with either atypical presentation or atypical course from neurodegenerative disease other than AD was ranked as poor. The consensus recommendation was reached on Delphi round I (6 of 7 panellists voted affirmatively for clinical use).
PICO 8: FDG-PET for differentiating between DLB and AD
One hundred and twenty-nine papers were identified and screened by the designated panellist (ZW), but only 29 were selected as adequate for assessment and sent to the methodology team (see Fig. 1 -PICO 8). Of these, 16 papers were excluded, as follows: (i) one did not include the population of interest [30] ; (ii) eight did not compare DLB and AD patients [31] [32] [33] [34] [35] [36] [37] [38] ; (iii) one was an epidemiologic study [39] ; (iv) two were methodological studies for quantitative analyses of FDG-PET [40, 41] ; and (v) four reported only patterns of hypometabolism (rather than quantitative diagnostic data) [42] [43] [44] [45] . The detailed data extraction table is available at:https://drive.google.com/open? id=0B0_JB3wzTvbpUHhIMVpHTkhBMEU.
Critical outcomes were available in 11 of the examined papers (Table 4) . However, the reference standard in the majority of these papers was clinical diagnosis at baseline; only two studies, including a total of 23 DLB and 31 AD patients, quantified test performance appropriately. Overall, these papers found a 70-92% sensitivity range, 74-100% specificity range and 72-96% accuracy range [29, 37, [46] [47] [48] [49] [50] [51] [52] [53] ; 0.77-0.91 AUC range [48, 50, [52] [53] [54] ; and 86% PPV, 85% NPV and 4.46 LH+ [46] . Studies reporting only hypometabolic patterns disclosed a partially overlapping profile of brain hypometabolism in AD and DLB, except for a marked hypometabolism in the visual cortex in DLB and relative preservation of metabolism in the posterior cingulate cortex (cingulate island sign; see Fig. 2A and D).
Taking into account the available evidence for the PICOs of the entire project, the level of evidence supporting the clinical utility of FDG-PET in distinguishing between DLB and AD patients was ranked as good. The consensual recommendation was defined on Delphi round I, as six panellists voted to support clinical use for discriminating DLB and AD, because of the specific metabolic patterns.
PICO 9: FDG-PET for differentiating AD from FTLD
Among the 137 papers identified by the panellist (FB), 15 were sent to the methodology team (see Fig. 1 -PICO 9). Table 2 Evidence and panellists' decisions supporting the use of FDG-PET in the diagnostic work-up of the main forms of dementia. Panellists supported the use of FDG-PET for the other PICO questions [16] [17] [18] , with the exception of those relative to preclinical conditions [19] , Huntington disease and amyotrophic lateral sclerosis [20] PICO Seven papers were excluded, as follows: (i) four papers did not report critical outcomes and did not reach the minimum sample size [34, [55] [56] [57] ; (ii) two papers did not compare AD and FTLD patients in a manner that provided useful information for a differential diagnosis [58, 59] ; and (iii) one paper did not include both target groups (i.e. only FTLD patients) [60] . The data extraction table is available at:https://drive.google. com/open?id=0B0_JB3wzTvbpUmZtWTFsYkVYY0E. Critical outcomes were available in five of the selected papers (Table 5 ). Sensitivity was in the 80-99% range, specificity ranged from 63% to 98%, and accuracy from 87% to 89.2% [52, [61] [62] [63] . The other values were as follows: AUC range of 0.91-0.97 [52, 63] ; 98% PPV, 74% NPV, 29.88 LR+, 0.25 LR− [63] ; and increased accuracy for the classification of FTLD with respect to AD by using semi-quantitative assessment of FDG-PET [36] . The remaining papers reported only differences in patterns of hypometabolism ( Fig. 2A and E) . One study [64] provided quantitative information on the discrimination between AD (or FTLD) and other pathologies, but did not directly compare AD and FTLD. Thus, this information did not address our question (AD vs FTLD+DLB: sensitivity = 94%, specificity = 86%, AUC = 0.90, LR+ = 6.71, LR − = 0.07; FTLD vs AD+DLB: sensitivity = 93%, specificity = 95%, accuracy = 0.94, LR+ = 18.6, LR− = 0.07). Another paper with the same indirect comparisons found that FDG-PET correctly classified 88.1% of AD and 83.9% of FTLD [65] . The remaining paper [66] provided only associated patterns of hypometabolism, describing metabolic differences between AD and HC, FTLD and HC, and AD and FTLD, without diagnostic metrics.
Relative to the available evidence for the PICOs of the entire project, the availability of formal evidence supporting the diagnostic utility of FDG-PET in distinguishing AD from FTLD patients was ranked as fair. The consensual recommendation was defined on Delphi round I, with all seven panellists supporting clinical diagnostic use because the typical metabolic patterns are backed by some evidence and were judged as very useful for differential diagnosis.
PICO 10: FDG-PET for differentiating between DLB and FTLD
Among the 80 papers identified by the designated panellist (ZW), 13 were sent to the methodology team (see Fig. 1 -PICO 10). Eight papers were excluded: (i) three papers were reviews; (ii) one was not in English; (iii) two did not include the population of interest [38, 67] ; and (iv) two did not compare DLB patients and FTLD patients [49, 60] . The data extraction table is available at: https://drive.google.com/open? id=0B0_JB3wzTvbpbUJLeVc3MW8waU0.
Critical outcomes were available in only one of the examined papers (Table 6 ). This study reported 71% sensitivity, 65% specificity, 66% accuracy and 68% AUC for FDG-PET in distinguishing between DLB and FTLD patients [52] . However, values were obtained using only the baseline clinical diagnosis as the reference standard. The remaining papers provided only descriptive evidence of the metabolic pattern associated with each disorder. Different patterns of hypometabolism associated with the two disorders consisted of a predominantly posterior hypometabolism in DLB and predominantly anterior hypometabolism in FTLD patients, but also an overlap in several areas (i.e. parieto-temporal cortex, posterior cingulate; see Fig. 2D and E) .
Relative to the evidence available for the other PICOs, the availability of formal evidence supporting the diagnostic utility of FDG-PET in distinguishing DLB from FTLD patients was lacking. Consensual recommendation was reached on Delphi round II, when six panellists voted for clinical use, because all considered the typical metabolic patterns to be useful in supporting the differential diagnosis between the two conditions.
PICO 11: Use of FDG-PET for differentiating between AD and VaD
The designated panellist (PN) identified 16 papers that were sent to the methodology team (see Fig. 1 -PICO 11) . Nine papers were excluded for the following reasons: (i) the target samples were missing in five papers [56, [68] [69] [70] [71] ; (ii) one study used oxygen-15 PET rather than FDG-PET [72] ; and (iii) three did not address the comparison of interest [73] [74] [75] . The data extraction table is available at: https://drive.google. com/open?id=0B0_JB3wzTvbpUVFRN2NPalplZGM.
Critical outcomes were available in only one of the remaining papers (Table 7) . With the obvious drawback that the testing sample was the same used to train the algorithm, AD patients, VaD patients and controls were identified with 100% accuracy, sensitivity and specificity by applying a fully automated, voxel-based multivariate technique [76] . Patterns of hypometabolism associated with VaD patients included thalamus, brainstem and cerebellum, as opposed to AD patients who showed hypometabolism in the posterior cingulate and temporo-parietal cortex [76] [77] [78] . These patterns were not, however, replicated in other studies [79, 80] .
Formal evidence supporting the diagnostic utility of FDG-PET in distinguishing AD from VaD patients was considered as lacking. The consensual recommendation was reached at Delphi round II, with five panellists voting for supporting clinical use, as they considered that the metabolic pattern typically found in AD patients could help support the differential diagnosis between AD and VaD.
PICO 14: FDG-PET for discriminating depressive pseudodementia
No studies were obtained for this PICO question; therefore we lack evidence regarding the diagnostic utility of FDG-PET in 
Discussion
In this paper, we have assessed evidence for the utility of FDG-PET in differential diagnosis among the main forms of dementing disorders, specifically AD, FTLD, DLB, VaD and pseudodementia. Based on data extraction and assessment, we found no conclusive evidence for the diagnostic utility of FDG-PET in discriminating DLB from FTLD, VaD from AD, and pseudodementia from neurodegenerative disorders. Conversely, we found fair relative availability of evidence to support the use of FDG-PET for differentiating AD from FTLD, and poor relative availability of evidence for distinguishing among atypical forms of AD. It should be noted that in these instances, the lack of evidence was due to a paucity of appropriate studies rather than studies with negative results. There was good evidence supporting the use of the exam for differentiating AD from DLB. Despite the general lack of evidence, consensus supporting the use of FDG-PET was reached for all PICO questions during Delphi voting. It is important to stress, however, that a positive recommendation for use of FDG-PET in a specific clinical circumstance must not be construed as meaning it should be a routine investigation whenever that circumstance arises. When the clinical picture is completely classic for some of the degenerative dementias, the addition of FDG-PET is unlikely to significantly increase diagnostic certainty. For instance, a patient with a progressive disorder characterised by prominent visuospatial and attention deficits, spontaneous parkinsonism, visual hallucination, fluctuation and REM sleep behaviour disorder has probable DLB [13] . Likewise, a patient with progressive changes in behaviour and personality characteristic of the behavioural variant of frontotemporal dementia (bvFTD) combined with disproportionate frontal lobe atrophy on structural imaging has probable FTLD [7] . Although in these two vignettes, one would expect FDG-PET to also show characteristic changes, the pre-test probability of the diagnosis is already so high that adding FDG-PET is superfluous. This caveat is acknowledged in the wording of several national guidelines in Europe (Table 1) , which stress that the indication for FDG-PET is in circumstances where the clinical picture and standard structural imaging (i.e. without PET) is 'unclear' or 'in doubt'. The question then arises as to what defines 'unclear' or 'in doubt'. This is a complex SPM statistical parametric mapping (please see legend for Table 3 ) question that should take into account not only the degree of diagnostic uncertainty, but also the implications of an incorrect diagnosis; this can mean that even fairly minor doubt may justify FDG-PET. To illustrate this, consider again a patient whose informant reports behaviour and personality changes that are consistent with bvFTD, but this time the structural imaging does not show unequivocal frontal lobe atrophy, and in whom it is hard to be sure from the informant's account whether the symptoms are truly progressive. This is a common clinical scenario in which bvFTD may still remain the most likely diagnosis; however, now-and in spite of only a fairly subtle change in the clinical information-there is a very real possibility that the patient may not have a degenerative disease at all; this vignette is also compatible with a so-called FTD phenocopy syndrome. In this scenario, FDG-PET can play a critical role, in that frontal hypometabolism offers strong evidence for the diagnosis of bvFTD [81] .
Atypical AD (PICO 7)
The occurrence of atypical AD may be difficult to detect at the individual level, where merging of multiple biomarkers is often needed to reach a correct diagnosis. In this context, FDG-PET may be especially useful in identifying patients with AD pathology among those presenting with primary progressive aphasia (PPA), and indeed it is included in the current diagnostic criteria for this purpose [11] . For further discussion on the role of FDG-PET in discriminating between the variants of PPA, see also [16] in this issue. The PCA variant of AD can sometimes be particularly difficult to diagnose, especially for clinicians with limited experience with the syndrome. Patients often struggle to articulate their difficulties, and complaints of visual disturbance in the absence of ocular disease can even lead to misdiagnosis of a functional psychological disorder. This is often further compounded by the young age of many PCA patients, which means that dementia is not suspected. In this context, FDG-PET can prove particularly helpful, as it characteristically shows extensive posterior cortical hypometabolism. What can be more complex, however, is discrimination of the PCA variant of AD from DLB, although the cingulate island sign is increasingly recognised in DLB and not in AD, although the remaining posterior association cortex may disclose largely overlapping regions of hypometabolism between the two conditions. DLB/typical AD (PICO 8) The reason for the positive response by the majority of panellists was based on the available data, providing relatively good-quality evidence of the ability for FDG-PET to discriminate DLB from AD. The inclusion of FDG-PET in the new criteria for DLB [13] as a supportive biomarker also contributed to the panellists' decision. In this context, however, the panellists recognised that radiopharmaceuticals targeting the brain presynaptic dopaminergic pathway or cardiac post-ganglionic norepinephrine transporter are more accurate in differentiating DLB from AD. FDG-PET may have a role, especially in centres where these examinations are unavailable.
Ad/FTLD (PICO 9) The panellists acknowledged that differentiating FTLD from AD on clinical-neuropsychological grounds alone may sometimes be challenging (e.g. in situations where reliable informant history is limited). In most cases, the hypometabolic patterns of FTLD and AD are clearly distinguished. FTLD patients show variable amounts of hypometabolism of the prefrontal, insular and anterior cingulate cortex and basal ganglia. Conversely, hypometabolism involves the posterior cingulate cortex, the precuneus and variable degrees of the posterior temporal and parietal cortex in AD patients. Some degree of hypometabolism can, however, also be found in parietal cortex in FTLD patients, though this is characteristically less pronounced than the prefrontal lesion. Moreover, some degree of hypometabolism can be found in the frontal association cortex in AD patients and ultimately becomes a universal feature as the disease progresses. The posterior regions are, however, characteristically more severely affected than the frontal lobes. In summary, therefore, although posterior association cortex hypometabolism may occur in FTLD and prefrontal hypometabolism occurs AD, it is the relative gradient-rostral worse than caudal in FTLD and vice versa in AD-that has discriminant value.
Despite relatively few quantitative studies, FDG-PET has been approved in the USA for discriminating FTD from AD [Decision Memo for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for Suspected Dementia (CAG-00088R), 2004], and included in the clinical criteria of both bv-FTD [7] and PPA [11] . Moreover, the EANM procedural guidelines [82] state that 'Indications include early diagnosis and differential diagnosis of dementing disorders, such as Alzheimer's disease and frontotemporal dementia'. However, there may remain occasional cases where a diagnosis cannot be reached based on clinical-neuropsychological ev aluation and FDG-PET, since fro nto-p arietal hypometabolism may sometimes be found in both diseases, whose degree is generally correlated with the severity of the disease stage. In these cases, amyloid biomarkers may be more informative, albeit with the caveat that a positive amyloid biomarker may be an incidental finding (especially with elderly presentations) in FTLD [83, 84] -i.e. minor AD copathology in a patient whose dementia is caused by FTLD. In these cases, a clear FTLD pattern on FDG-PET might help point to the causal diagnosis, whereas a positive amyloid biomarker along with left posterior temporo-parietal hypometabolism (i.e. the FDG-PET signature of lvPPA) would argue for AD as the causal pathology.
DLB/FTLD (PICO 10)
The reason given by the majority of panellists for use in this scenario was the clearly different patterns of hypometabolism associated with the two conditions, FTLD showing frontal and anterior-temporal hypometabolism and DLB displaying mainly posterior involvement (visual cortex and parieto-temporal cortex) and relative posterior cingulate preservation (cingulate island sign). Although some degree of frontal lobe hypometabolism can be found in DLB, it is not predominant. Most cases can be differentiated clinically, meaning that FDG-PET is seldom necessary, but there are some overlapping clinical features and misdiagnosis between the two conditions has been reported in autopsy cases [85] [86] [87] .
Furthermore, parkinsonism may be present in both conditions, and presynaptic dopaminergic imaging may be abnormal in both disorders. The inclusion of FDG-PET in the bvFTD criteria [7] and the new DLB criteria [13] also contributed to the panellists' decision.
AD/VaD (PICO 11) A key problem with the concept of VaD, and possibly a reason for inconsistencies among studies, lies in the huge heterogeneity of VaD patients, who differ in terms of etiology, number, location and extent of vascular lesions. There is also the issue of mixed pathologies, in that a patient with symptomatic vascular lesions can also show AD pathology. Lastly, in patients with dementia and severe vascular lesions on MRI, dementia may not necessarily be due to vascular pathology-clear-cut temporal and qualitative relationships must be demonstrated per the criteria for vascular cognitive impairment [88] . In patients with AD and concomitant vascular lesions, it may be difficult to establish the relative weight of the two components in causing the clinical dementia. The existing literature in this field is particularly limited, as we lack studies with pathological diagnosis as the reference standard. Moreover, the comparison among available studies is problematic because of the variable inclusion criteria for VaD. With these caveats in mind, the consensual recommendation for clinical utility was achieved, supporting the use of FDG-PET in identifying AD in patients with vascular pathology when the characteristic AD pattern of bilateral posterior temporo-parietal hypometabolism can be shown, and provided that these hypometabolic regions are not co-localised with cortical infarcts on structural scans. On this final point, FDG-PET should never be reported without review of the structural imaging; this is good clinical practice in all cases of suspected degenerative brain disease, but none more so than where vascular lesions are suspected.
Pseudodementia (PICO 14)
Depressive pseudodementia is a relatively uncommon problem, but it is critical not to miss it because of its potential reversibility. No formal studies on the utility of FDG-PET in this context were identified. Nonetheless, there was unanimous consensus by the panellists supporting the use of FDG-PET. The rationale is, firstly, based on the knowledge that FDG-PET abnormalities are a function of disease severity. Thus, a clearly demented patient should always have obvious abnormalities on FDG-PET. A normal FDG-PET in this instance offers strong evidence supporting pseudodementia, while a typical pattern of hypometabolism for one of the degenerative dementias argues against pseudodementia (high NPV). It should be noted here that subtle frontal hypometabolism may be found in some patients with severe depression, but the hypometabolic profiles corresponding to the degenerative diseases that cause dementia are far from subtle. Finally, it must be stressed that this recommendation specifically applies to a patient with an apparent overt dementia on cognitive testing, and not to the more common and challenging situation of deciding whether patients with very mild or even subjective cognitive deficits have a primary psychiatric diagnosis versus the first signs of a degenerative disease (see [19] in this issue for discussion of subjective and mild cognitive impairment).
The key limitation of this work was the paucity or, in some circumstances, complete lack of evidence on which to base recommendations. Even where evidence exists, limitations in study design often raise questions about the applicability of results to real-world clinical practice. For instance, many studies assess accuracy metrics using baseline clinical diagnosis as the reference standard. The baseline clinical diagnosis, however, can be incorrect. Therefore, both baseline clinical diagnosis and FDG-PET should be assessed versus an independent reference standard; ideally this reference should be pathology, although a biomarker-based diagnosis may offer a surrogate (if a valid biomarker is available) or, at the very least, versus diagnosis at clinical follow-up (although this last option is better suited to outcome studies in subjective or mild cognitive impairment than to differential diagnosis). Lack of a definitive reference standard is arguably most pertinent to VaD, in which the vascular risk factors and lesions used to make the 'diagnosis' may be incidental/additional findings, while the primary cause of the dementia is degenerative.
Even if one assumes that in past studies using baseline clinical diagnosis as reference standard, this clinical diagnosis was 100% correct, problems still remain. Consider a hypothetical study contrasting AD and FTLD that reports an impressive 90% accuracy for discriminating the two conditions with FDG-PET. If the clinical information was good enough to diagnose patients with 100% accuracy, then 90% accuracy for the diagnostic investigation no longer looks impressive. Indeed, in Bayesian terms, the test has added nothing. Conversely, interpreting accuracy where-as is probably the case in many studies-the clinical diagnosis was not always correct can unfairly penalise the accuracy results for FDG-PET (e.g. a patient with AD pathology whose FDG-PET also showed the characteristic hypometabolic pattern of AD, but who had been misdiagnosed clinically as bvFTD, would be recorded as a failure for FDG-PET if clinical diagnosis were being used as the reference standard).
The real worth of FDG-PET-or any diagnostic test for that matter-is not in confirming what was already obvious, but in improving accuracy where some uncertainty exists. In many clinical scenarios there is uncertainty, and often only a subtle degree of uncertainty is sufficient for the test to add value. In order to ascertain how much added value, more studies with pathological confirmation as the reference standard-and comparing head-to-head with the accuracy of clinical diagnosis-are essential. It is, at least theoretically, possible that in some circumstances FDG-PET might outperform standard clinical diagnosis, but this is impossible to prove when clinical diagnosis is used as the benchmark. Prospective studies with pathological confirmation require time and effort. On a positive note, however, the definitive information achieved from such an approach likely means that useful information can be found with far fewer cases than in a purely clinical study. Furthermore, the stability of FDG-PET between scanners makes it ideal for pooling data across centres, meaning that many sites, each with only a few datasets, can still play a useful role. Finally, future analyses of diagnostic potential need to adopt more Bayesian approaches in order to understand the true added value for FDG-PET.
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